IRIS UniCatt

Di Giambenedetto, Simona
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.807
EU - Europa 10.324
AS - Asia 9.315
SA - Sud America 1.988
AF - Africa 306
OC - Oceania 43
Continente sconosciuto - Info sul continente non disponibili 12
AN - Antartide 1
Totale 34.796
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.397
SG - Singapore 4.340
DE - Germania 2.568
CN - Cina 2.075
BR - Brasile 1.636
SE - Svezia 1.571
FR - Francia 1.269
IT - Italia 1.235
PL - Polonia 825
VN - Vietnam 806
UA - Ucraina 635
IE - Irlanda 477
GB - Regno Unito 467
IN - India 417
NL - Olanda 412
ID - Indonesia 312
FI - Finlandia 293
JP - Giappone 225
CA - Canada 205
RU - Federazione Russa 190
HK - Hong Kong 189
AR - Argentina 151
TR - Turchia 147
BD - Bangladesh 141
MX - Messico 117
IQ - Iraq 102
ZA - Sudafrica 86
PK - Pakistan 71
ES - Italia 65
BE - Belgio 63
AT - Austria 62
IR - Iran 57
SA - Arabia Saudita 51
KR - Corea 45
MA - Marocco 44
VE - Venezuela 39
EC - Ecuador 38
PH - Filippine 36
UZ - Uzbekistan 36
LT - Lituania 35
AU - Australia 34
CO - Colombia 33
KE - Kenya 31
EG - Egitto 30
CH - Svizzera 28
JO - Giordania 28
CL - Cile 26
TN - Tunisia 26
CI - Costa d'Avorio 25
PY - Paraguay 23
KZ - Kazakistan 22
MY - Malesia 21
AZ - Azerbaigian 20
IL - Israele 19
AE - Emirati Arabi Uniti 17
JM - Giamaica 17
PE - Perù 16
CZ - Repubblica Ceca 14
OM - Oman 14
NP - Nepal 13
TW - Taiwan 13
UY - Uruguay 13
LB - Libano 12
AL - Albania 11
BO - Bolivia 11
CM - Camerun 11
CR - Costa Rica 11
DZ - Algeria 11
GR - Grecia 11
HN - Honduras 11
PA - Panama 11
RO - Romania 11
NG - Nigeria 10
PT - Portogallo 10
TH - Thailandia 10
DO - Repubblica Dominicana 9
EU - Europa 9
PS - Palestinian Territory 9
BH - Bahrain 8
ET - Etiopia 8
KG - Kirghizistan 8
NZ - Nuova Zelanda 8
BG - Bulgaria 7
LV - Lettonia 7
MD - Moldavia 7
NI - Nicaragua 7
QA - Qatar 7
TT - Trinidad e Tobago 7
DK - Danimarca 6
LK - Sri Lanka 6
NO - Norvegia 6
RS - Serbia 6
BY - Bielorussia 5
HR - Croazia 5
LA - Repubblica Popolare Democratica del Laos 5
CY - Cipro 4
GE - Georgia 4
HU - Ungheria 4
KW - Kuwait 4
SY - Repubblica araba siriana 4
Totale 34.714
Salva come PNG Salva come JPEG
Città #
Singapore 2.239
Chandler 1.920
Ashburn 1.485
San Jose 1.104
Kraków 599
New York 537
Dublin 469
Jacksonville 420
Beijing 404
San Mateo 382
Amsterdam 381
Milan 309
Jakarta 280
Lauterbourg 277
Los Angeles 275
Ho Chi Minh City 271
Nanjing 227
Rome 222
Wilmington 221
Warsaw 206
Boston 204
Tokyo 198
Hanoi 196
Hefei 190
Ann Arbor 186
Houston 181
The Dalles 179
Dearborn 164
Hong Kong 160
Dallas 144
São Paulo 144
Frankfurt am Main 136
Princeton 127
Cattolica 126
Lawrence 122
Chicago 119
Nürnberg 110
Munich 108
Helsinki 107
Moscow 107
Woodbridge 107
Redwood City 104
Nanchang 95
St Louis 95
Seattle 92
Santa Clara 90
Orem 85
Marseille 83
Buffalo 74
Redmond 74
Izmir 67
London 67
Boardman 64
Montreal 61
Brussels 60
Nuremberg 60
Lancaster 59
Fairfield 58
Brooklyn 56
Bremen 55
Düsseldorf 55
Paris 54
Shenyang 52
Atlanta 50
Mountain View 50
Rio de Janeiro 50
Johannesburg 49
Toronto 48
Kent 47
Pune 47
Norwalk 45
Poplar 44
Changsha 43
Kunming 42
Chennai 41
Guangzhou 41
Augusta 40
Shanghai 40
Denver 39
Haiphong 39
Vienna 39
Council Bluffs 38
Da Nang 37
Hebei 37
Tianjin 37
University Park 37
Ottawa 35
Belo Horizonte 34
Hangzhou 34
Turku 34
Phoenix 33
Seoul 33
Stockholm 33
Verona 33
Mexico City 31
Washington 31
Baghdad 30
Manchester 30
Tashkent 29
Amman 28
Totale 18.331
Salva come PNG Salva come JPEG
Nome #
Functional associations between polymorphic regions of the human 3'IgH locus and COVID-19 disease 796
Post-COVID-19 global health strategies: the need for an interdisciplinary approach 526
Novel sensitive, specific and rapid pharmacogenomic test for the prediction of abacavir hypersensitivity reaction: HLA-B*57:01 detection by real-time PCR 381
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study) 267
Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility 253
Fatigue in Covid-19 survivors: The potential impact of a nutritional supplement on muscle strength and function 230
Post-COVID-19 global health strategies: the need for an interdisciplinary approach 227
Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis 226
Prevalence of osteoporosis and predictors of low BMD in a cohort of HIV-1-infected patients in Rome: features of a population at high risk 218
Liver fibrosis is associated with cognitive impairment in HIV-positive patients 218
Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre 217
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study) 210
Fatigue in Covid-19 survivors: The potential impact of a nutritional supplement on muscle strength and function 208
Neuropsychological screening tools in Italian HIV+ patients: a comparison of Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE) 201
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2 years follow-up in HIV-infected patients 199
Evaluation of emotion processing in HIV-infected patients and correlation with cognitive performance 194
Assessment of neurological manifestations in hospitalized patients with COVID-19 193
Residual respiratory impairment after COVID-19 pneumonia 190
Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study 190
Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients 189
Ophthalmic artery resistance index IS increased in HIV-Infected patients and is influenced by protease inhibitors exposure 186
Gemelli decision tree Algorithm to Predict the need for home monitoring or hospitalization of confirmed and unconfirmed COVID-19 patients (GAP-Covid19): preliminary results from a retrospective cohort study 185
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study 185
Relationship between antiretroviral plasma concentration and emergence of HIV-1 resistance mutations at treatment failure 185
Verbal list learning and memory profiles in HIV-infected adults, Alzheimer's disease, and Parkinson's disease: An evaluation of the "cortical hypothesis" of NeuroAIDS 184
Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA 183
Clinical presentation, microbiological features and correlates of disease severity of 2009 pandemic influenza A (H1N1) infection 182
Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen. 181
Variability of raltegravir plasma levels in the clinical setting 181
Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure. 176
Prospective evaluation of epidemiological, clinical, and microbiological features of pandemic influenza A (H1N1) virus infection in Italy 176
The effect of polymorphisms in candidate genes on the long-term risk of lipodystrophy and dyslipidemia in HIV-infected white patients starting antiretroviral therapy 176
Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia 175
Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010. 173
Dolutegravir Plus Lamivudine as First-Line Regimen in a Multicenter Cohort of HIV-1-Infected Patients: Preliminary Data from Clinical Practice 171
Asymmetry of the regimen is correlated to self-reported suboptimal adherence: results from AdUCSC, a cohort study on adherence in Italy. 169
Predictors of successful genotype-guided antiretroviral therapy in treatment-experienced individuals over calendar year: a cohort study 167
Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction 167
Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients 166
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) 166
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients 165
Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial 165
Validation of an UPLC-MS/MS Method for Quantitative Analysis of Raltegravir in Human Plasma Samples 162
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine versus the 23-valent polysaccharide vaccine in unvaccinated HIV-infected adults: A pilot, prospective controlled study 162
Shall we dance? Extending tango's results to clinical practice 160
Macrophage chemoattractant protein-1 levels in cerebrospinal fluid correlate with containment of JC virus and prognosis of acquired immunodeficiency syndrome--associated progressive multifocal leukoencephalopathy. 158
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2-year follow-up in HIV-infected patients 158
Cognitive reserve and neuropsychological functioning in older HIV-infected people 156
Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis 155
Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection 155
Virological suppression reduces clinical progression in patients with multiclass-resistant HIV type 1 154
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients 154
Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy 154
Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort) 153
Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients 153
Are mutations in HIV type-1 reverse transcriptase 245 codon predictive of abacavir hypersensitivity reaction? 152
Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure 152
Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: two years experience in routine clinical practice 150
Asymmetry of the regimen is correlated to self-reported suboptimal adherence: results from AdUCSC, a cohort study on adherence in Italy 150
Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients 149
Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study 149
Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study. 148
Increased ophthalmic artery resistance index is associated with cognitive impairment in HIV-infected patients. 148
Cardiovascular risk factors and carotid intima-media thickness are associated with low cognitive performance in HIV-infected patients 148
Cardiovascular Disease Risk in a Cohort of Virologically Suppressed People Living with HIV Switching to Doravirine: Preliminary Data from the Real Life 147
Mitochondrial DNA haplogroups and incidence of lipodystrophy in HIV-infected patients on long-term antiretroviral therapy 147
Bone mineral density improvement after 48 weeks of switch to maraviroc+darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA study 147
Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study 147
Cohort profile: The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE) 147
Decreased plasma levels of darunavir/ritonavir in a vertically infected pregnant woman carrying multiclass-resistant HIV type-1 147
Are we ready for long-acting? A feasibility evaluation of long-acting cabotegravir–rilpivirine in clinical practice 147
HIV-Related Internalized Stigma and Patient Health Engagement Model in an Italian Cohort of People Living With HIV 146
Difference in the neurocognitive functions of WLWH and MLWH in an Italian cohort of people living with HIV 146
Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection. 145
Effect of aging and human immunodeficiency virus infection on cognitive abilities 144
Mortality in patients with early- or late-onset candidaemia 142
HIV-infected patients show impaired cellular immune response to influenza vaccination, compared to healthy subjects 142
Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen 142
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial 142
Comparison of cognitive performance in HIV or HCV mono-infected and HIV-HCV co-infected patients 141
Long term follow-up of Nevirapine-treated patients in a single centre cohort 139
Prevalence of transmitted HIV-1 drug resistance in HIV-1 infected patients in Italy: evolution over 12 years and predictors 139
Detection of HLA-B*57:01 by real-time PCR: implementation into routine clinical practice and additional validation data 138
Psychological distress during the initial stage of the COVID-19 pandemic in an italian population living with HIV: An online survey 138
Genotypic resistance profile and clinical progression of treatment-experienced HIV type 1-infected patients with virological failure. 137
Declining Prevalence of HIV-1 Drug Resistance in Antiretroviral Treatment-exposed Individuals in Western Europe 137
Cardiovascular risk factors and carotid intima-media thickness are associated with lower cognitive performance in HIV-infected patients 137
A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients 137
SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV 137
Hospital reengineering against COVID-19 outbreak: 1-month experience of an Italian tertiary care center 137
Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping 136
Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: A multicenter observational study 136
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial 136
Changes in bone mineral density in HIV-positive, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy: preliminary results from clinical practice 136
Lamivudine-based maintenance antiretroviral therapies in patients living with HIV-1 with suppressed HIV RNA: derivation of a predictive score for virological failure 136
The University of California San Diego performance-based skills assessment: a useful tool to detect mild everyday functioning difficulties in HIV-infected patients with very good immunological condition 136
Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial 135
Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: A retrospective study from the clinical practice 135
Genotypic resistance to lopinavir and fosamprenavir with or without ritonavir of clinical isolates from patients failing protease inhibitors-containing HAART regimens: prevalence and predictors 134
Mortality in patients, with early-or late-onset candidaemia 134
Totale 17.626
Salva come PNG Salva come JPEG
Categoria #
all - tutte 141.381
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 141.381
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021376 0 0 0 0 0 0 0 0 0 84 251 41
2021/20222.197 183 132 44 183 81 65 100 382 81 161 310 475
2022/20235.312 667 752 449 795 475 677 166 404 619 87 160 61
2023/20242.711 105 690 61 318 115 530 129 51 69 82 306 255
2024/20254.989 83 115 471 167 477 199 235 279 734 446 976 807
2025/202612.640 1.947 350 777 1.610 2.295 1.280 2.096 614 801 870 0 0
Totale 35.242